What question did this study set out to answer?

To compare the efficacy and safety of treosulfan-fludarabine versus reduced-intensity busulfan-fludarabine in AML patients undergoing alloHCT.

February 2, 2026HaematologicaOpen Access

GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial

View Full Paper

Ask AI

Bookmark

Authors

FSFriedrich StölzelKiel University MSMatthias StelljesUniversity Hospital Münster BDBeelen DwEssen University Hospital

Discussion

Member takes

Implication

Subgroup analysis compares the effects of treosulfan versus busulfan on outcomes in AML patients undergoing transplant, suggesting improved efficacy for treosulfan.

Key Points

To compare the efficacy and safety of treosulfan-fludarabine versus reduced-intensity busulfan-fludarabine in AML patients undergoing alloHCT.
Subgroup analysis of phase 3 MC-FludT.14/L trial
Comparison of two conditioning regimens in 352 AML patients aged 31–70
Assessment of event-free survival, overall survival, GVHD incidence, relapse rates, and non-relapse mortality
Treosulfan showed a higher 24-month event-free survival (65% vs. 53%, p = 0.01)
Treosulfan demonstrated superiority in overall survival (73% vs. 65%)
Lower incidence of extensive chronic GVHD with treosulfan (15.1% vs. 28.1%, p = 0.01)
Improved GVHD-free and relapse-free survival (53% vs. 40%, p = 0.02)
Treosulfan had a more favorable safety profile

Cite This Study

Stölzel et al. (2026) studied this question.

synapsesocial.com/papers/6980fc55c1c9540dea80e2cc https://doi.org/10.3324/haematol.2025.288770

View Full Paper

Ask AI

Bookmark

Implication

Subgroup analysis compares the effects of treosulfan versus busulfan on outcomes in AML patients undergoing transplant, suggesting improved efficacy for treosulfan.

GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider